| Literature DB >> 33926508 |
Fenghua Tan1,2, Mengyao Zhao1,2, Fang Xiong3, Yumin Wang2,3, Shanshan Zhang3, Zhaojian Gong4, Xiayu Li5, Yi He1, Lei Shi4, Fuyan Wang2, Bo Xiang1,2, Ming Zhou1,2, Xiaoling Li1,2, Yong Li6, Guiyuan Li1,2, Zhaoyang Zeng1,2, Wei Xiong7,8, Can Guo9,10.
Abstract
The N6-methyladenosine (m6A) modification is a dynamic and reversible epigenetic modification, which is co-transcriptionally deposited by a methyltransferase complex, removed by a demethylase, and recognized by reader proteins. Mechanistically, m6A modification regulates the expression levels of mRNA and nocoding RNA by modulating the fate of modified RNA molecules, such as RNA splicing, nuclear transport, translation, and stability. Several studies have shown that m6A modification is dysregulated in the progression of multiple diseases, especially human tumors. We emphasized that the dysregulation of m6A modification affects different signal transduction pathways and involves in the biological processes underlying tumor cell proliferation, apoptosis, invasion and migration, and metabolic reprogramming, and discuss the effects on different cancer treatment.Entities:
Keywords: Cancer progression; N6-methyladenosine; RNA fate; Signal transduction pathway; Therapy
Year: 2021 PMID： 33926508 DOI： 10.1186/s13046-021-01952-4
Source DB: PubMed Journal: J Exp Clin Cancer Res ISSN： 0392-9078